AU2015217788B2 - Benzimidazol-2-amines as mIDH1 inhibitors - Google Patents
Benzimidazol-2-amines as mIDH1 inhibitors Download PDFInfo
- Publication number
- AU2015217788B2 AU2015217788B2 AU2015217788A AU2015217788A AU2015217788B2 AU 2015217788 B2 AU2015217788 B2 AU 2015217788B2 AU 2015217788 A AU2015217788 A AU 2015217788A AU 2015217788 A AU2015217788 A AU 2015217788A AU 2015217788 B2 AU2015217788 B2 AU 2015217788B2
- Authority
- AU
- Australia
- Prior art keywords
- amino
- phenyl
- trimethylcyclohexyl
- alkyl
- propanoic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 0 CN(*)C(C=C)=O Chemical compound CN(*)C(C=C)=O 0.000 description 6
- FOGDJGPYRKLYQB-LYLHDHRRSA-N CC(C)(C[C@@H](C1)C#C)CC1(C1)[C@@H]1Nc(cccc1F)c1N Chemical compound CC(C)(C[C@@H](C1)C#C)CC1(C1)[C@@H]1Nc(cccc1F)c1N FOGDJGPYRKLYQB-LYLHDHRRSA-N 0.000 description 1
- FMOCXCJXQNNEOZ-NBNXLVQJSA-N C[C@@H](C1)CC(C)(C)CC1(C1)[C@@H]1Nc(cccc1F)c1N Chemical compound C[C@@H](C1)CC(C)(C)CC1(C1)[C@@H]1Nc(cccc1F)c1N FMOCXCJXQNNEOZ-NBNXLVQJSA-N 0.000 description 1
- IYOHUGNSEBHVSY-MBIQTGHCSA-N C[C@@H](C1)CC(C)(C)CC1[n]1c(Nc(cc2)ccc2OC(F)F)nc2c1ccc(C(O)=O)c2 Chemical compound C[C@@H](C1)CC(C)(C)CC1[n]1c(Nc(cc2)ccc2OC(F)F)nc2c1ccc(C(O)=O)c2 IYOHUGNSEBHVSY-MBIQTGHCSA-N 0.000 description 1
- QHGLOAVXKVNAGX-PZJWPPBQSA-N C[C@@H](C1)CC(C)(C)C[C@@H]1[n]1c(Nc(cc2)ccc2OC(F)(F)F)nc2c1ccc(OCC(Nc(cccc1)c1Cl)=O)c2 Chemical compound C[C@@H](C1)CC(C)(C)C[C@@H]1[n]1c(Nc(cc2)ccc2OC(F)(F)F)nc2c1ccc(OCC(Nc(cccc1)c1Cl)=O)c2 QHGLOAVXKVNAGX-PZJWPPBQSA-N 0.000 description 1
- PUPROOVAAOCOHL-XMLVGPMBSA-N C[C@@H](C1)CC(C)(C)C[C@@]1(C1)[C@@H]1Nc(cc(c(CCC(O)=O)c1)OC)c1N Chemical compound C[C@@H](C1)CC(C)(C)C[C@@]1(C1)[C@@H]1Nc(cc(c(CCC(O)=O)c1)OC)c1N PUPROOVAAOCOHL-XMLVGPMBSA-N 0.000 description 1
- DPACXOKFAFFKDA-QWRGUYRKSA-N C[C@@H](C1)CC(C)(C)C[C@H]1Nc(cccc1F)c1N Chemical compound C[C@@H](C1)CC(C)(C)C[C@H]1Nc(cccc1F)c1N DPACXOKFAFFKDA-QWRGUYRKSA-N 0.000 description 1
- XFCQXVFNTCIAAH-HIFRSBDPSA-N C[C@H](C1)CC(C)(C)C[C@H]1Nc(cc(c(CCC(OC)=O)c1)OC)c1N Chemical compound C[C@H](C1)CC(C)(C)C[C@H]1Nc(cc(c(CCC(OC)=O)c1)OC)c1N XFCQXVFNTCIAAH-HIFRSBDPSA-N 0.000 description 1
- DPACXOKFAFFKDA-MNOVXSKESA-N C[C@H](C1)CC(C)(C)C[C@H]1Nc(cccc1F)c1N Chemical compound C[C@H](C1)CC(C)(C)C[C@H]1Nc(cccc1F)c1N DPACXOKFAFFKDA-MNOVXSKESA-N 0.000 description 1
- FVDYNRUDUUBQTR-QAPCUYQASA-N C[C@H](C1)CC(C)(C)C[C@H]1[n]1c(Nc(cc2)ccc2OC(C)(F)F)nc2c1ccc(C(O)=O)c2 Chemical compound C[C@H](C1)CC(C)(C)C[C@H]1[n]1c(Nc(cc2)ccc2OC(C)(F)F)nc2c1ccc(C(O)=O)c2 FVDYNRUDUUBQTR-QAPCUYQASA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14154680.4 | 2014-02-11 | ||
| EP14154680 | 2014-02-11 | ||
| EP14182002 | 2014-08-22 | ||
| EP14182002.7 | 2014-08-22 | ||
| PCT/EP2015/052676 WO2015121210A1 (en) | 2014-02-11 | 2015-02-10 | Benzimidazol-2-amines as midh1 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2015217788A1 AU2015217788A1 (en) | 2016-08-04 |
| AU2015217788B2 true AU2015217788B2 (en) | 2019-06-27 |
Family
ID=52462928
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2015217788A Ceased AU2015217788B2 (en) | 2014-02-11 | 2015-02-10 | Benzimidazol-2-amines as mIDH1 inhibitors |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US9957235B2 (enExample) |
| EP (1) | EP3105209B1 (enExample) |
| JP (1) | JP6534675B2 (enExample) |
| KR (1) | KR20160115991A (enExample) |
| CN (1) | CN106573897B (enExample) |
| AP (1) | AP2016009371A0 (enExample) |
| AU (1) | AU2015217788B2 (enExample) |
| BR (1) | BR112016018604A2 (enExample) |
| CA (1) | CA2939026A1 (enExample) |
| CL (1) | CL2016002033A1 (enExample) |
| CR (1) | CR20160361A (enExample) |
| CU (1) | CU24410B1 (enExample) |
| DO (1) | DOP2016000208A (enExample) |
| EA (1) | EA031655B1 (enExample) |
| IL (1) | IL246785A0 (enExample) |
| MX (1) | MX2016010474A (enExample) |
| PE (1) | PE20170143A1 (enExample) |
| PH (1) | PH12016501581A1 (enExample) |
| SG (1) | SG11201605810WA (enExample) |
| SV (1) | SV2016005257A (enExample) |
| TW (1) | TWI666202B (enExample) |
| UY (1) | UY35991A (enExample) |
| WO (1) | WO2015121210A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20170143A1 (es) | 2014-02-11 | 2017-03-19 | Bayer Pharma AG | Benzimidazol-2-aminas como inhibidores de midh1 |
| CN105980365B (zh) | 2014-02-11 | 2019-06-21 | 拜耳医药股份公司 | 作为mIDH1抑制剂的苯并咪唑-2-胺 |
| HUE062424T2 (hu) | 2014-09-19 | 2023-11-28 | Forma Therapeutics Inc | Piridin-2(1H)-on kinolinon származékok mint mutáns izocitrát dehidrogenáz inhibitorok |
| WO2016044781A1 (en) | 2014-09-19 | 2016-03-24 | Forma Therapeutics, Inc. | Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors |
| US10138226B2 (en) * | 2014-10-23 | 2018-11-27 | Bayer Pharma Aktiengesellschaft | Benzimidazol-2-amines as MIDH1 inhibitors |
| JP6672288B2 (ja) | 2014-10-23 | 2020-03-25 | バイエル・ファルマ・アクティエンゲゼルシャフト | 腫瘍の治療のためのｍｉｄｈ１阻害剤としての１−シクロヘキシル−２−フェニルアミノベンゾイミダゾール |
| EP3303302B1 (en) * | 2015-06-08 | 2019-03-20 | Bayer Pharma Aktiengesellschaft | N-menthylbenzimidazoles as midh1 inhibitors |
| WO2017005674A1 (en) * | 2015-07-07 | 2017-01-12 | Bayer Pharma Aktiengesellschaft | 2-aryl- and 2-arylalkyl-benzimidazoles as midh1 inhibitors |
| CN108026052B (zh) * | 2015-07-16 | 2021-10-08 | 德国癌症研究公共权益基金会 | 作为mIDH1抑制剂的5-羟烷基苯并咪唑类 |
| EP3121166A1 (en) | 2015-07-21 | 2017-01-25 | Bayer Pharma Aktiengesellschaft | Fused imidazoles as midh1 inhibitors |
| TW201708193A (zh) * | 2015-07-27 | 2017-03-01 | 拜耳製藥公司 | 突變之異檸檬酸脫氫酶ｉｄｈ１ ｒ１３２ｈ之抑制劑 |
| TW201718513A (zh) * | 2015-07-27 | 2017-06-01 | 拜耳製藥公司 | 製備經取代之３－（２－苯胺－１－環己基－１ｈ－苯并咪唑－５－基）丙酸衍生物之方法 |
| MX2018009633A (es) | 2016-02-09 | 2018-12-17 | Inventisbio Inc | Inhibidor de indoleamina-2,3-dioxigenasa (ido). |
| WO2019015672A1 (zh) * | 2017-07-21 | 2019-01-24 | 南京明德新药研发股份有限公司 | 吡啶并咪唑类化合物及其应用 |
| JP2020535112A (ja) * | 2017-08-01 | 2020-12-03 | ドイッチェス・クレープスフォルシュングスツェントルムＤｅｕｔｓｃｈｅｓ Ｋｒｅｂｓｆｏｒｓｃｈｕｎｇｓｚｅｎｔｒｕｍ | Ｍｉｄｈ１阻害剤とｄｎａ低メチル化剤（ｈｍａ）との組合せ |
| US11013734B2 (en) | 2018-05-16 | 2021-05-25 | Forma Therapeutics, Inc. | Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation |
| SMT202300073T1 (it) | 2018-05-16 | 2023-05-12 | Forma Therapeutics Inc | Inibizione di idh-1 mutante |
| WO2019222551A1 (en) | 2018-05-16 | 2019-11-21 | Forma Therapeutics, Inc. | Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile |
| US11013733B2 (en) | 2018-05-16 | 2021-05-25 | Forma Therapeutics, Inc. | Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1) |
| US11311527B2 (en) | 2018-05-16 | 2022-04-26 | Forma Therapeutics, Inc. | Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1) |
| AU2019296173B2 (en) * | 2018-06-26 | 2022-01-06 | Kpc Pharmaceuticals, Inc. | Benzimidazole derivatives and use thereof as IDH1 inhibitors |
| TWI760017B (zh) * | 2019-12-23 | 2022-04-01 | 大陸商昆藥集團股份有限公司 | 一種ｉｄｈ１突變體抑制劑的鹽型、晶型及其製備方法 |
| US12014835B2 (en) | 2020-02-19 | 2024-06-18 | Vanderbilt University | Methods for evaluating therapeutic benefit of combination therapies |
| US20230270814A1 (en) * | 2020-07-21 | 2023-08-31 | Daiichi Sankyo Company, Limited | Combination pharmaceutical of temozolomide and mutant idh1 enzyme inhibitor |
| CN112062687B (zh) * | 2020-09-02 | 2023-11-21 | 上海信谊万象药业股份有限公司 | 一种盐酸阿扎司琼中间体3-氨基-5-氯-2-羟基苯甲酸甲酯的合成方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008153701A1 (en) * | 2007-05-24 | 2008-12-18 | Schering Corporation | Compounds for inhibiting ksp kinesin activity |
| WO2010151441A1 (en) * | 2009-06-23 | 2010-12-29 | Translational Genomics Research Institute | Benzamide derivatives |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2643903A1 (fr) | 1989-03-03 | 1990-09-07 | Union Pharma Scient Appl | Nouveaux derives de benzimidazole, leurs procedes de preparation, intermediaires de synthese, compositions pharmaceutiques les contenant, utiles notamment pour le traitement des maladies cardiovasculaires, et des ulceres duodenaux |
| CN1161340C (zh) | 1998-11-30 | 2004-08-11 | 先灵公司 | 为玻连蛋白受体拮抗剂的苯并咪唑化合物 |
| US6340681B1 (en) | 1999-07-16 | 2002-01-22 | Pfizer Inc | 2-benzimidazolylamine compounds as ORL-1-receptor agonists |
| US6448281B1 (en) | 2000-07-06 | 2002-09-10 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
| US7030150B2 (en) | 2001-05-11 | 2006-04-18 | Trimeris, Inc. | Benzimidazole compounds and antiviral uses thereof |
| CA2448737C (en) | 2001-07-20 | 2010-06-01 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
| CA2477505A1 (en) | 2002-03-01 | 2003-09-12 | Smithkline Beecham Corporation | Diamino-pyrimidines and their use as angiogenesis inhibitors |
| US7531553B2 (en) | 2003-03-21 | 2009-05-12 | Amgen Inc. | Heterocyclic compounds and methods of use |
| US7714009B2 (en) | 2003-10-31 | 2010-05-11 | Takeda Pharmaceutical Company Limited | Nitrogen-containing fused heterocyclic compounds |
| WO2005121132A1 (ja) | 2004-06-11 | 2005-12-22 | Shionogi & Co., Ltd. | 抗ｈｃｖ作用を有する縮合ヘテロ環化合物 |
| JPWO2006038738A1 (ja) | 2004-10-08 | 2008-05-15 | 武田薬品工業株式会社 | 受容体機能調節剤 |
| US20060223849A1 (en) | 2005-03-14 | 2006-10-05 | Mjalli Adnan M | Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors |
| US8168800B2 (en) | 2007-11-02 | 2012-05-01 | The Regents Of The University Of California | Aβ-binding small molecules |
| WO2009116074A2 (en) | 2008-02-13 | 2009-09-24 | Cadila Healthcare Limited | Substituted benzimidazoles as cannabinoid modulator |
| UY32138A (es) | 2008-09-25 | 2010-04-30 | Boehringer Ingelheim Int | Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables |
| UY32470A (es) | 2009-03-05 | 2010-10-29 | Boehringer Ingelheim Int | Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones |
| WO2011072174A1 (en) | 2009-12-09 | 2011-06-16 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds for use in the treatment of cancer characterized as having an idh mutation |
| WO2012172043A1 (en) * | 2011-06-15 | 2012-12-20 | Laboratoire Biodim | Purine derivatives and their use as pharmaceuticals for prevention or treatment of bacterial infections |
| CN102827170A (zh) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
| CN103435554A (zh) | 2013-09-06 | 2013-12-11 | 中国药科大学 | 2-苯氨基苯并咪唑类化合物及其用途 |
| CN105980365B (zh) | 2014-02-11 | 2019-06-21 | 拜耳医药股份公司 | 作为mIDH1抑制剂的苯并咪唑-2-胺 |
| PE20170143A1 (es) | 2014-02-11 | 2017-03-19 | Bayer Pharma AG | Benzimidazol-2-aminas como inhibidores de midh1 |
| US10138226B2 (en) | 2014-10-23 | 2018-11-27 | Bayer Pharma Aktiengesellschaft | Benzimidazol-2-amines as MIDH1 inhibitors |
| JP6672288B2 (ja) | 2014-10-23 | 2020-03-25 | バイエル・ファルマ・アクティエンゲゼルシャフト | 腫瘍の治療のためのｍｉｄｈ１阻害剤としての１−シクロヘキシル−２−フェニルアミノベンゾイミダゾール |
| AU2016264220A1 (en) | 2015-05-18 | 2018-01-04 | Translational Drug Development Llc | Heterocyclic compounds as kinase inhibitors |
| CN107921126A (zh) | 2015-05-22 | 2018-04-17 | 转化药物开发有限责任公司 | 苯甲酰胺和活性化合物的组合物及其使用方法 |
| EP3303302B1 (en) | 2015-06-08 | 2019-03-20 | Bayer Pharma Aktiengesellschaft | N-menthylbenzimidazoles as midh1 inhibitors |
| WO2017005674A1 (en) | 2015-07-07 | 2017-01-12 | Bayer Pharma Aktiengesellschaft | 2-aryl- and 2-arylalkyl-benzimidazoles as midh1 inhibitors |
| CN108026052B (zh) | 2015-07-16 | 2021-10-08 | 德国癌症研究公共权益基金会 | 作为mIDH1抑制剂的5-羟烷基苯并咪唑类 |
| EP3121166A1 (en) | 2015-07-21 | 2017-01-25 | Bayer Pharma Aktiengesellschaft | Fused imidazoles as midh1 inhibitors |
| TW201708193A (zh) | 2015-07-27 | 2017-03-01 | 拜耳製藥公司 | 突變之異檸檬酸脫氫酶ｉｄｈ１ ｒ１３２ｈ之抑制劑 |
| TW201718513A (zh) | 2015-07-27 | 2017-06-01 | 拜耳製藥公司 | 製備經取代之３－（２－苯胺－１－環己基－１ｈ－苯并咪唑－５－基）丙酸衍生物之方法 |
| CA3053238A1 (en) | 2016-03-02 | 2017-09-08 | Translational Drug Development Llc | Aminobenzimidazole derivatives |
-
2015
- 2015-02-10 PE PE2016001465A patent/PE20170143A1/es unknown
- 2015-02-10 WO PCT/EP2015/052676 patent/WO2015121210A1/en not_active Ceased
- 2015-02-10 US US15/118,154 patent/US9957235B2/en not_active Expired - Fee Related
- 2015-02-10 CN CN201580019265.9A patent/CN106573897B/zh not_active Expired - Fee Related
- 2015-02-10 BR BR112016018604A patent/BR112016018604A2/pt not_active Application Discontinuation
- 2015-02-10 AP AP2016009371A patent/AP2016009371A0/en unknown
- 2015-02-10 EA EA201691590A patent/EA031655B1/ru not_active IP Right Cessation
- 2015-02-10 CU CU2016000120A patent/CU24410B1/es unknown
- 2015-02-10 AU AU2015217788A patent/AU2015217788B2/en not_active Ceased
- 2015-02-10 KR KR1020167024825A patent/KR20160115991A/ko not_active Withdrawn
- 2015-02-10 MX MX2016010474A patent/MX2016010474A/es unknown
- 2015-02-10 EP EP15703288.9A patent/EP3105209B1/en active Active
- 2015-02-10 SG SG11201605810WA patent/SG11201605810WA/en unknown
- 2015-02-10 CR CR20160361A patent/CR20160361A/es unknown
- 2015-02-10 JP JP2016551221A patent/JP6534675B2/ja not_active Expired - Fee Related
- 2015-02-10 CA CA2939026A patent/CA2939026A1/en not_active Abandoned
- 2015-02-11 TW TW104104623A patent/TWI666202B/zh not_active IP Right Cessation
- 2015-02-11 UY UY0001035991A patent/UY35991A/es not_active Application Discontinuation
-
2016
- 2016-07-14 IL IL246785A patent/IL246785A0/en unknown
- 2016-08-10 PH PH12016501581A patent/PH12016501581A1/en unknown
- 2016-08-11 CL CL2016002033A patent/CL2016002033A1/es unknown
- 2016-08-11 DO DO2016000208A patent/DOP2016000208A/es unknown
- 2016-08-11 SV SV2016005257A patent/SV2016005257A/es unknown
-
2018
- 2018-03-16 US US15/923,895 patent/US10442772B2/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008153701A1 (en) * | 2007-05-24 | 2008-12-18 | Schering Corporation | Compounds for inhibiting ksp kinesin activity |
| WO2010151441A1 (en) * | 2009-06-23 | 2010-12-29 | Translational Genomics Research Institute | Benzamide derivatives |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106573897B (zh) | 2019-09-24 |
| AP2016009371A0 (en) | 2016-08-31 |
| MX2016010474A (es) | 2016-10-31 |
| UY35991A (es) | 2015-09-30 |
| SV2016005257A (es) | 2018-10-02 |
| PE20170143A1 (es) | 2017-03-19 |
| US20170197921A1 (en) | 2017-07-13 |
| CL2016002033A1 (es) | 2017-03-31 |
| KR20160115991A (ko) | 2016-10-06 |
| IL246785A0 (en) | 2016-08-31 |
| CU20160120A7 (es) | 2016-12-23 |
| CN106573897A (zh) | 2017-04-19 |
| JP2017505790A (ja) | 2017-02-23 |
| PH12016501581A1 (en) | 2017-02-06 |
| BR112016018604A2 (pt) | 2017-08-08 |
| EA201691590A1 (ru) | 2017-02-28 |
| JP6534675B2 (ja) | 2019-06-26 |
| AU2015217788A1 (en) | 2016-08-04 |
| US10442772B2 (en) | 2019-10-15 |
| US9957235B2 (en) | 2018-05-01 |
| EP3105209B1 (en) | 2019-08-21 |
| US20190062285A1 (en) | 2019-02-28 |
| CR20160361A (es) | 2016-10-03 |
| CU24410B1 (es) | 2019-05-03 |
| TW201613874A (en) | 2016-04-16 |
| SG11201605810WA (en) | 2016-08-30 |
| EP3105209A1 (en) | 2016-12-21 |
| WO2015121210A1 (en) | 2015-08-20 |
| CA2939026A1 (en) | 2015-08-20 |
| EA031655B1 (ru) | 2019-02-28 |
| TWI666202B (zh) | 2019-07-21 |
| DOP2016000208A (es) | 2016-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10442772B2 (en) | Benzimidazol-2-amines as mIDH1 inhibitors | |
| ES2732902T3 (es) | Bencimidazol-2-aminas como inhibidores de MIDH1 | |
| US11524944B2 (en) | 2-phenylpyrimidine-4-carboxamides as AHR inhibitors | |
| EP3209646B1 (en) | Benzimidazol-2-amines as midh1 inhibitors | |
| EP3209660B1 (en) | 1-cyclohexyl-2-phenylaminobenzimidazoles as midh1 inhibitors for the treatment of tumors | |
| US20200283402A1 (en) | 3-oxo-6-heteroaryl-2-phenyl-2,3-dihydropyridazine-4-carboxamides | |
| CA2992364A1 (en) | 5-hydroxyalkylbenzimidazoles as midh1 inhibitors | |
| CA2992960A1 (en) | Fused imidazoles as midh1 inhibitors | |
| CA2991360A1 (en) | 2-aryl- and 2-arylalkyl-benzimidazoles as midh1 inhibitors | |
| HK1236531A1 (en) | Benzimidazol-2-amines as midh1 inhibitors | |
| HK1226398B (en) | Benzimidazol-2-amines as midh1 inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| PC | Assignment registered |
Owner name: DEUTSCHES KREBSFORSCHUNGSZENTRUM, STIFTUNG DES OEFFENTLICHEN RECHTS Free format text: FORMER OWNER(S): BAYER PHARMA AKTIENGESELLSCHAFT |
|
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |